Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q3 2026 › vs Q3 2025
Tonix Pharmaceuticals Holding (TNXP) Q3 2026 vs Q3 2025 (year over year)
Tonix Pharmaceuticals Holding's revenue rose $13.9M (+424%) from $3.3M in Q3 2025 to $17.2M in Q3 2026. The biggest changes: Zembrace Symtouch −$1.1M (-41%); Tosymra −$19K (-3%).
Tonix Pharmaceuticals Holding, Q3 2026: revenue $17.2M (+424% year over year), operating margin -321.6%, net loss $53.3M, operating cash flow −$41.1M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Zembrace Symtouch | $1.5M | $2.6M | −$1.1M | -41% |
| Tosymra | $689K | $708K | −$19K | -3% |
| Revenue | $17.2M | $3.3M | $13.9M | +424% |
| Other income, net | $2.1M | $1.1M | $1.0M | +99% |
| Net loss | $53.3M | $32.0M | $21.3M | +67% |
| Costs & expenses | $72.7M | $36.4M | $36.3M | +100% |
| Operating costs | $72.7M | $36.4M | $36.3M | +100% |
| Cost of revenue | $1.3M | $1.4M | −$115K | -8% |
| Research & development | $25.8M | $9.3M | $16.5M | +178% |
| SG&A | $45.6M | $25.7M | $19.9M | +77% |
| Operating cash sources | $53.3M | $32.0M | $21.3M | +67% |
| Depreciation & amortization | $643K | $461K | $182K | +39% |
| Share-based compensation | $2.3M | $1.9M | $370K | +19% |
| Working capital & other | $9.3M | $844K | $8.5M | 11× |
| Cash used in operations | $41.1M | $28.8M | $12.3M | +43% |
| Net loss absorbed | $53.3M | $32.0M | $21.3M | +67% |
Questions
How much did Tonix Pharmaceuticals Holding's revenue grow year over year in Q3 2026?
Tonix Pharmaceuticals Holding's revenue rose $13.9M (+424%) from $3.3M in Q3 2025 to $17.2M in Q3 2026.
What drove Tonix Pharmaceuticals Holding's revenue change in Q3 2026?
Zembrace Symtouch −$1.1M (-41%); Tosymra −$19K (-3%).